Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

Praxis Precision Medicines (NASDAQ: PRAX) will report third-quarter 2026 financial results before markets open on November 9, 2026.

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) will report third-quarter 2026 financial results before markets open on November 9, 2026.

The company will host an in-person and live-webcast Investor Day in New York on November 12 at 8:00 a.m. ET. Management will discuss commercial strategy and launch readiness for ulixacaltamide for Essential Tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, both under FDA review, and provide a pipeline update. Praxis will also participate in Guggenheim’s conference on November 9, UBS’s conference on November 16 and Jefferies investor meetings on November 17–18.

Key Figures

Q3 results date: November 9, 2026

Q3 results date

November 9, 2026

Financial results scheduled before market open

Key Terms

central nervous system, essential tremor, developmental and epileptic encephalopathies

3 terms

central nervous system medical

"leading central nervous system (CNS) precision neuroscience biopharmaceutical company"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

essential tremor medical

"ulixacaltamide for Essential Tremor"

Essential tremor is a neurological condition that causes involuntary shaking, usually in the hands or arms, which can make everyday tasks difficult. While it is not life-threatening, it can impact a person's ability to perform precise movements. For investors, understanding such health conditions is important because they can influence a person's productivity, decision-making, and overall financial stability.

developmental and epileptic encephalopathies medical

"relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies"

Developmental and epileptic encephalopathies are a group of severe brain disorders that begin early in life, causing significant challenges with learning, development, and seizures. These conditions can limit a child's ability to grow and function normally, often requiring ongoing medical care. For investors, understanding these disorders highlights areas of medical research and treatment development that could lead to new therapies and market opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host an in-person and virtual Investor Day on November 12, 2026

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.

Investor Day

Praxis will host an Investor Day in New York on Thursday, November 12, 2026, at 8:00 a.m. ET. The event will be held in person and webcast live. To register, click here.

The Investor Day will include presentations from senior management on the Company’s commercial strategy and launch readiness for the two programs under FDA review: ulixacaltamide for Essential Tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies. Key opinion leaders will join management to discuss the unmet need and current treatment landscape in each indication. Management will also provide an update on the Company’s robust pipeline.

November Investor Conference Participation

• Guggenheim Securities Inaugural Healthcare Innovation Conference: a fireside chat will take place on Monday, November 9, 2026, at 9:30 a.m. ET at the InterContinental Boston in Boston, MA. A live webcast will be available here.
  
• UBS Global Biopharma Conference: a fireside chat will take place on Monday, November 16, 2026, at 5:40 a.m. ET / 10:40 a.m. GMT at the Rosewood in London, UK. A live webcast will be available here.
  
• Jefferies Global Healthcare Conference: senior management will participate in investor one-on-one meetings on Tuesday, November 17, 2026, and Wednesday, November 18, 2026, at the Waldorf Hilton in London, UK.
  

Replays of the Investor Day and fireside chats, where webcast, will be available on Praxis’ “Events and Presentations” website after each event for approximately 90 days.

About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders for small molecules through Cerebrum™, and for antisense oligonucleotides (ASOs) through Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576